Opportunities for the treatment of atherosclerosis: Selectins
Despite the widespread availability of selectins for tumor therapy, their contribution to atherosclerosis has long been under-emphasized due to their “cofactor’s” status and technological limitations. However, advances in immunohistology, glycomics, and related technologies require us to reassess th...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-07-01
|
| Series: | Pharmacological Research |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S1043661825002324 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Despite the widespread availability of selectins for tumor therapy, their contribution to atherosclerosis has long been under-emphasized due to their “cofactor’s” status and technological limitations. However, advances in immunohistology, glycomics, and related technologies require us to reassess their relationship. Thus, this review identifies pivotal translational opportunities from the intricate mechanisms and explores the clinical promise of selectins in the diagnosis and treatment of atherosclerosis based on the latest clinical research. This review provides insights into selectin-specific tracers and inhibitors, providing lessons for more precise diagnosis and treatment of patients with atherosclerosis. |
|---|---|
| ISSN: | 1096-1186 |